Abstract
A disintegrin and metalloproteases (ADAMs) are key mediators of cell signaling by ectodomain shedding of various growth factors, cytokines, receptors and adhesion molecules at the cellular membrane. ADAMs regulate cell proliferation, cell growth, inflammation, and other regular cellular processes. ADAM17, the most extensively studied ADAM family member, is also known as tumor necrosis factor (TNF)-α converting enzyme (TACE). ADAMs-mediated shedding of cytokines such as TNF-α orchestrates immune system or inflammatory cascades and ADAMs-mediated shedding of growth factors causes cell growth or proliferation by transactivation of the growth factor receptors including epidermal growth factor receptor. Therefore, increased ADAMs-mediated shedding can induce inflammation, tissue remodeling and dysfunction associated with various cardiovascular diseases such as hypertension and atherosclerosis, and ADAMs can be a potential therapeutic target in these diseases. In this review, we focus on the role of ADAMs in cardiovascular pathophysiology and cardiovascular diseases. The main aim of this review is to stimulate new interest in this area by highlighting remarkable evidence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cho C (2012) Testicular and epididymal ADAMs: expression and function during fertilization. Nat Rev Urol 9(10):550–560. https://doi.org/10.1038/nrurol.2012.167
Brocker CN, Vasiliou V, Nebert DW (2009) Evolutionary divergence and functions of the ADAM and ADAMTS gene families. Hum Genomics 4(1):43–55. https://doi.org/10.1186/1479-7364-4-1-43
Moss M, Jin S, Milla M, Bickett D, Burkhart W, Carter H, Chen W, Clay W, Didsbury J, Hassler D, Hoffman C, Kost T, Lambert M, Leesnitzer M, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton L, Schoenen F, Seaton T, Su J, Becherer J (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385(6618):733–736
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385(6618):729–733. https://doi.org/10.1038/385729a0
Black RA, White JM (1998) ADAMs: focus on the protease domain. Curr Opin Cell Biol 10(5):654–659
Blobel CP (1997) Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell 90(4):589–592
Lorenzen I, Trad A, Grotzinger J (2011) Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun 415(2):330–336. https://doi.org/10.1016/j.bbrc.2011.10.056
Schlondorff J, Becherer JD, Blobel CP (2000) Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J 347(Pt 1):131–138
Wong E, Maretzky T, Peleg Y, Blobel CP, Sagi I (2015) The functional maturation of A disintegrin and metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site. J Biol Chem 290(19):12135–12146. https://doi.org/10.1074/jbc.M114.624072
Wiley H, Woolf M, Opresko L, Burke P, Will B, Morgan J, Lauffenburger D (1998) Removal of the membrane-anchoring domain of epidermal growth factor leads to intracrine signaling and disruption of mammary epithelial cell organization. J Cell Biol 143(5):1317–1328
Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22(5):1114–1124. https://doi.org/10.1093/emboj/cdg111
Forrester SJ, Kawai T, O’Brien S, Thomas W, Harris RC, Eguchi S (2016) Epidermal growth factor receptor transactivation: mechanisms, pathophysiology, and potential therapies in the cardiovascular system. Annu Rev Pharmacol Toxicol 56:627–653. https://doi.org/10.1146/annurev-pharmtox-070115-095427
Elliott KJ, Bourne AM, Takayanagi T, Takaguri A, Kobayashi T, Eguchi K, Eguchi S (2013) ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells. J Mol Cell Cardiol 62:1–7. https://doi.org/10.1016/j.yjmcc.2013.05.005
George AJ, Hannan RD, Thomas WG (2013) Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. FEBS J 280(21):5258–5268. https://doi.org/10.1111/febs.12509
Ohtsu H, Dempsey PJ, Eguchi S (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291(1):C1-10. https://doi.org/10.1152/ajpcell.00620.2005
Blobel CP (2005) ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6(1):32–43. https://doi.org/10.1038/nrm1548
Kinugasa Y, Hieda M, Hori M, Higashiyama S (2007) The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 282(20):14797–14806. https://doi.org/10.1074/jbc.M611036200
Nanba D, Mammoto A, Hashimoto K, Higashiyama S (2003) Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163(3):489–502. https://doi.org/10.1083/jcb.200303017
Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, Shudou M, Taguchi T, Hieda Y, Higashiyama S (2008) Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 180(4):763–769. https://doi.org/10.1083/jcb.200710022
Bell JH, Herrera AH, Li Y, Walcheck B (2007) Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol 82(1):173–176. https://doi.org/10.1189/jlb.0307193
Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA (2000) Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275(19):14608–14614. https://doi.org/10.1074/jbc.275.19.14608
Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 63(5):321–329. https://doi.org/10.1111/j.1365-3083.2006.01750.x
Gooz M (2010) ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 45(2):146–169. https://doi.org/10.3109/10409231003628015
Krossa S, Scheidig AJ, Grotzinger J, Lorenzen I (2018) Redundancy of protein disulfide isomerases in the catalysis of the inactivating disulfide switch in A disintegrin and metalloprotease 17. Sci Rep 8(1):1103. https://doi.org/10.1038/s41598-018-19429-4
Kunzel U, Grieve AG, Meng Y, Sieber B, Cowley SA, Freeman M (2018) FRMD8 promotes inflammatory and growth factor signalling by stabilising the iRhom/ADAM17 sheddase complex. Elife. https://doi.org/10.7554/eLife.35012
Dombernowsky SL, Samsoe-Petersen J, Petersen CH, Instrell R, Hedegaard AM, Thomas L, Atkins KM, Auclair S, Albrechtsen R, Mygind KJ, Frohlich C, Howell M, Parker P, Thomas G, Kveiborg M (2015) The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17. Nat Commun 6:7518. https://doi.org/10.1038/ncomms8518
Kakiashvili E, Dan Q, Vandermeer M, Zhang Y, Waheed F, Pham M, Szaszi K (2011) The epidermal growth factor receptor mediates tumor necrosis factor-alpha-induced activation of the ERK/GEF-H1/RhoA pathway in tubular epithelium. J Biol Chem 286(11):9268–9279. https://doi.org/10.1074/jbc.M110.179903
Mendelson K, Swendeman S, Saftig P, Blobel CP (2010) Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways. J Biol Chem 285(32):25024–25032. https://doi.org/10.1074/jbc.M110.102566
Xu P, Derynck R (2010) Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 37(4):551–566. https://doi.org/10.1016/j.molcel.2010.01.034
Gooz M, Gooz P, Luttrell LM, Raymond JR (2006) 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem 281(30):21004–21012. https://doi.org/10.1074/jbc.M512096200
Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, Hooper A, Rafii S, Blobel CP (2008) VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 103(9):916–918. https://doi.org/10.1161/CIRCRESAHA.108.184416
Prakasam HS, Gallo LI, Li H, Ruiz WG, Hallows KR, Apodaca G (2014) A1 adenosine receptor-stimulated exocytosis in bladder umbrella cells requires phosphorylation of ADAM17 Ser-811 and EGF receptor transactivation. Mol Biol Cell 25(23):3798–3812. https://doi.org/10.1091/mbc.E14-03-0818
Dang M, Armbruster N, Miller MA, Cermeno E, Hartmann M, Bell GW, Root DE, Lauffenburger DA, Lodish HF, Herrlich A (2013) Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways. Proc Natl Acad Sci U S A 110(24):9776–9781. https://doi.org/10.1073/pnas.1307478110
Kommaddi RP, Thomas R, Ceni C, Daigneault K, Barker PA (2011) Trk-dependent ADAM17 activation facilitates neurotrophin survival signaling. FASEB J 25(6):2061–2070. https://doi.org/10.1096/fj.10-173740
Schwarz J, Schmidt S, Will O, Koudelka T, Kohler K, Boss M, Rabe B, Tholey A, Scheller J, Schmidt-Arras D, Schwake M, Rose-John S, Chalaris A (2014) Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor alpha ectodomain shedding. J Biol Chem 289(5):3080–3093. https://doi.org/10.1074/jbc.M113.536847
Le Gall SM, Maretzky T, Issuree PDA, Niu XD, Reiss K, Saftig P, Khokha R, Lundell D, Blobel CP (2010) ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 123(22):3913–3922. https://doi.org/10.1242/jcs.069997
Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, Rafii S, Reiss K, Blobel CP (2011) Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun 2:229. https://doi.org/10.1038/ncomms1232
Parr-Sturgess CA, Rushton DJ, Parkin ET (2010) Ectodomain shedding of the Notch ligand Jagged1 is mediated by ADAM17, but is not a lipid-raft-associated event. Biochem J 432(2):283–294. https://doi.org/10.1042/BJ20100321
Ushio-Fukai M, Alexander RW (2006) Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle. Hypertension 48(5):797–803. https://doi.org/10.1161/01.HYP.0000242907.70697.5d
Gratton JP, Bernatchez P, Sessa WC (2004) Caveolae and caveolins in the cardiovascular system. Circ Res 94(11):1408–1417. https://doi.org/10.1161/01.RES.0000129178.56294.17
Takaguri A, Shirai H, Kimura K, Hinoki A, Eguchi K, Carlile-Klusacek M, Yang B, Rizzo V, Eguchi S (2011) Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J Mol Cell Cardiol 50(3):545–551. https://doi.org/10.1016/j.yjmcc.2010.12.009
Moreno-Caceres J, Mainez J, Mayoral R, Martin-Sanz P, Egea G, Fabregat I (2016) Caveolin-1-dependent activation of the metalloprotease TACE/ADAM17 by TGF-beta in hepatocytes requires activation of Src and the NADPH oxidase NOX1. FEBS J. https://doi.org/10.1111/febs.13669
Takayanagi T, Crawford KJ, Kobayashi T, Obama T, Tsuji T, Elliott KJ, Hashimoto T, Rizzo V, Eguchi S (2014) Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase. Clin Sci (Lond) 126(11):785–794. https://doi.org/10.1042/CS20130660
Willems SH, Tape CJ, Stanley PL, Taylor NA, Mills IG, Neal DE, McCafferty J, Murphy G (2010) Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J 428(3):439–450. https://doi.org/10.1042/BJ20100179
Aragao AZ, Nogueira ML, Granato DC, Simabuco FM, Honorato RV, Hoffman Z, Yokoo S, Laurindo FR, Squina FM, Zeri AC, Oliveira PS, Sherman NE, Paes Leme AF (2012) Identification of novel interaction between ADAM17 (a disintegrin and metalloprotease 17) and thioredoxin-1. J Biol Chem 287(51):43071–43082. https://doi.org/10.1074/jbc.M112.364513
Granato DC, e Costa RAP, Kawahara R, Yokoo S, Aragao AZ, Domingues RR, Pauletti BA, Honorato RV, Fattori J, Figueira ACM, Oliveira PSL, Consonni SR, Fernandes D, Laurindo F, Hansen HP, Paes Leme AF (2018) Thioredoxin-1 negatively modulates ADAM17 activity through direct binding and indirect reductive activity. Antioxid Redox Signal 29(8):717–734. https://doi.org/10.1089/ars.2017.7297
Stawikowska R, Cudic M, Giulianotti M, Houghten RA, Fields GB, Minond D (2013) Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J Biol Chem 288(31):22871–22879. https://doi.org/10.1074/jbc.M113.462267
Dusterhoft S, Michalek M, Kordowski F, Oldefest M, Sommer A, Roseler J, Reiss K, Grotzinger J, Lorenzen I (2015) Extracellular juxtamembrane segment of ADAM17 interacts with membranes and is essential for its shedding activity. Biochemistry 54(38):5791–5801. https://doi.org/10.1021/acs.biochem.5b00497
Sommer A, Kordowski F, Büch J, Maretzky T, Evers A, Andrä J, Düsterhöft S, Michalek M, Lorenzen I, Somasundaram P, Tholey A, Sönnichsen FD, Kunzelmann K, Heinbockel L, Nehls C, Gutsmann T, Grötzinger J, Bhakdi S, Reiss K (2016) Phosphatidylserine exposure is required for ADAM17 sheddase function. Nat Commun 7:11523. https://doi.org/10.1038/ncomms11523
Goth CK, Halim A, Khetarpal SA, Rader DJ, Clausen H, Schjoldager KT (2015) A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation. Proc Natl Acad Sci U S A 112(47):14623–14628. https://doi.org/10.1073/pnas.1511175112
McIlwain D, Lang P, Maretzky T, Hamada K, Ohishi K, Maney S, Berger T, Murthy A, Duncan G, Xu H, Lang K, Häussinger D, Wakeham A, Itie-Youten A, Khokha R, Ohashi P, Blobel C, Mak T (2012) iRhom2 regulation of TACE controls TNF-mediated protection against listeria and Responses to LPS. Science 335(6065):229–232
Maretzky T, McIlwain D, Issuree P, Li X, Malapeira J, Amin S, Lang P, Mak T, Blobel C (2013) iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. Proc Natl Acad Sci U S A 110(28):11433–11438
Adrain C, Zettl M, Christova Y, Taylor N, Freeman M (2012) Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 335(6065):225–228. https://doi.org/10.1126/science.1214400
Grieve AG, Xu H, Kunzel U, Bambrough P, Sieber B, Freeman M (2017) Phosphorylation of iRhom2 at the plasma membrane controls mammalian TACE-dependent inflammatory and growth factor signalling. Elife. https://doi.org/10.7554/eLife.23968
Li X, Maretzky T, Weskamp G, Monette S, Qing X, Issuree PD, Crawford HC, McIlwain DR, Mak TW, Salmon JE, Blobel CP (2015) iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. Proc Natl Acad Sci U S A 112(19):6080–6085. https://doi.org/10.1073/pnas.1505649112
Oikonomidi I, Burbridge E, Cavadas M, Sullivan G, Collis B, Naegele H, Clancy D, Brezinova J, Hu T, Bileck A, Gerner C, Bolado A, von Kriegsheim A, Martin SJ, Steinberg F, Strisovsky K, Adrain C (2018) iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE. Elife. https://doi.org/10.7554/eLife.35032
Cavadas M, Oikonomidi I, Gaspar CJ, Burbridge E, Badenes M, Felix I, Bolado A, Hu T, Bileck A, Gerner C, Domingos PM, von Kriegsheim A, Adrain C (2017) Phosphorylation of iRhom2 controls stimulated proteolytic shedding by the metalloprotease ADAM17/TACE. Cell Rep 21(3):745–757. https://doi.org/10.1016/j.celrep.2017.09.074
Babendreyer A, Rojas-González DM, Giese AA, Fellendorf S, Düsterhöft S, Mela P, Ludwig A (2020) Differential induction of the ADAM17 regulators iRhom1 and 2 in endothelial cells. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2020.610344
Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32(8):380–387. https://doi.org/10.1016/j.it.2011.05.005
Pruessmeyer J, Ludwig A (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol 20(2):164–174. https://doi.org/10.1016/j.semcdb.2008.09.005
Lisi S, D’Amore M, Sisto M (2014) ADAM17 at the interface between inflammation and autoimmunity. Immunol Lett 162(1 Pt A):159–169. https://doi.org/10.1016/j.imlet.2014.08.008
Obama T, Takayanagi T, Kobayashi T, Bourne AM, Elliott KJ, Charbonneau M, Dubois CM, Eguchi S (2015) Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1alpha. Am J Hypertens 28(1):10–14. https://doi.org/10.1093/ajh/hpu094
Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S (2006) ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26(9):e133-137. https://doi.org/10.1161/01.ATV.0000236203.90331.d0
Murphy G (2009) Regulation of the proteolytic disintegrin metalloproteinases, the ‘Sheddases.’ Semin Cell Dev Biol 20(2):138–145. https://doi.org/10.1016/j.semcdb.2008.09.004
Yoda M, Kimura T, Tohmonda T, Morioka H, Matsumoto M, Okada Y, Toyama Y, Horiuchi K (2013) Systemic overexpression of TNFalpha-converting enzyme does not lead to enhanced shedding activity in vivo. PLoS ONE 8(1):e54412. https://doi.org/10.1371/journal.pone.0054412
Takayanagi T, Forrester SJ, Kawai T, Obama T, Tsuji T, Elliott KJ, Nuti E, Rossello A, Kwok HF, Scalia R, Rizzo V, Eguchi S (2016) Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II. Hypertension 68(4):949–955. https://doi.org/10.1161/HYPERTENSIONAHA.116.07620
Takayanagi T, Kawai T, Forrester SJ, Obama T, Tsuji T, Fukuda Y, Elliott KJ, Tilley DG, Davisson RL, Park JY, Eguchi S (2015) Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II. Hypertension 65(6):1349–1355. https://doi.org/10.1161/HYPERTENSIONAHA.115.05344
Shen M, Morton J, Davidge ST, Kassiri Z (2017) Loss of smooth muscle cell disintegrin and metalloproteinase 17 transiently suppresses angiotensin II-induced hypertension and end-organ damage. J Mol Cell Cardiol 103:11–21. https://doi.org/10.1016/j.yjmcc.2016.12.001
Cicalese S, Okuno K, Eguchi S (2020) Novel methods article detection of protein aggregation and proteotoxicity induced by angiotensin II in vascular smooth muscle cells. J Cardiovasc Pharmacol. https://doi.org/10.1097/fjc.0000000000000934
Cicalese S, Okuno K, Elliott KJ, Kawai T, Scalia R, Rizzo V, Eguchi S (2020) 78 kDa glucose-regulated protein attenuates protein aggregation and monocyte adhesion induced by angiotensin II in vascular cells. Int J Mol Sci. https://doi.org/10.3390/ijms21144980
Cooper HA, Scalia R, Rizzo V, Eguchi S (2018) Angiotensin II- and Alzheimer-type cardiovascular aging. Circ Res 123(6):651–653. https://doi.org/10.1161/circresaha.118.313477
Okuno K, Cicalese S, Elliott KJ, Kawai T, Hashimoto T, Eguchi S (2020) Targeting molecular mechanism of vascular smooth muscle senescence induced by angiotensin II, a potential therapy via senolytics and senomorphics. Int J Mol Sci. https://doi.org/10.3390/ijms21186579
Xia H, Sriramula S, Chhabra KH, Lazartigues E (2013) Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Circ Res 113(9):1087–1096. https://doi.org/10.1161/CIRCRESAHA.113.301811
Mukerjee S, Gao H, Xu J, Sato R, Zsombok A, Lazartigues E (2019) ACE2 and ADAM17 interaction regulates the activity of presympathetic neurons. Hypertension 74(5):1181–1191. https://doi.org/10.1161/hypertensionaha.119.13133
Xu J, Sriramula S, Xia H, Moreno-Walton L, Culicchia F, Domenig O, Poglitsch M, Lazartigues E (2017) Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension. Circ Res 121(1):43–55. https://doi.org/10.1161/CIRCRESAHA.116.310509
Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi MF, Coudeyre JC, Alessi MC, Juhan-Vague I, Nalbone G (2006) The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 187(1):82–91. https://doi.org/10.1016/j.atherosclerosis.2005.08.031
Holdt LM, Thiery J, Breslow JL, Teupser D (2008) Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 28(6):1097–1103. https://doi.org/10.1161/ATVBAHA.108.165654
Zhao X, Kong J, Zhao Y, Wang X, Bu P, Zhang C, Zhang Y (2015) Gene silencing of TACE enhances plaque stability and improves vascular remodeling in a rabbit model of atherosclerosis. Sci Rep 5:17939. https://doi.org/10.1038/srep17939
Takaguri A, Kimura K, Hinoki A, Bourne AM, Autieri MV, Eguchi S (2011) A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 57(4):841–845. https://doi.org/10.1161/HYPERTENSIONAHA.110.166892
Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Hasler R, Becker C, Neurath MF, Reiss K, Saftig P, Scheller J, Rose-John S (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207(8):1617–1624. https://doi.org/10.1084/jem.20092366
Nicolaou A, Zhao Z, Northoff BH, Sass K, Herbst A, Kohlmaier A, Chalaris A, Wolfrum C, Weber C, Steffens S, Rose-John S, Teupser D, Holdt LM (2017) Adam17 deficiency promotes atherosclerosis by enhanced TNFR2 signaling in mice. Arterioscler Thromb Vasc Biol 37(2):247–257. https://doi.org/10.1161/ATVBAHA.116.308682
van der Vorst EP, Zhao Z, Rami M, Holdt LM, Teupser D, Steffens S, Weber C (2017) Contrasting effects of myeloid and endothelial ADAM17 on atherosclerosis development. Thromb Haemost 117(3):644–646. https://doi.org/10.1160/TH16-09-0674
Canault M, Leroyer AS, Peiretti F, Leseche G, Tedgui A, Bonardo B, Alessi MC, Boulanger CM, Nalbone G (2007) Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 171(5):1713–1723. https://doi.org/10.2353/ajpath.2007.070021
Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Jarvinen O, Salenius JP, Ozsait B, Komurcu-Bayrak E, Erginel-Unaltuna N, Huovila AP, Kytomaki L, Soini JT, Kahonen M, Karhunen PJ, Laaksonen R, Lehtimaki T (2009) ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries–Tampere vascular study. Ann Med 41(4):279–290. https://doi.org/10.1080/07853890802649738
Spin JM, Hsu M, Azuma J, Tedesco MM, Deng A, Dyer JS, Maegdefessel L, Dalman RL, Tsao PS (2011) Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm. Physiol Genomics 43(17):993–1003. https://doi.org/10.1152/physiolgenomics.00044.2011
Kaneko H, Anzai T, Horiuchi K, Kohno T, Nagai T, Anzai A, Takahashi T, Sasaki A, Shimoda M, Maekawa Y, Shimizu H, Yoshikawa T, Okada Y, Yozu R, Fukuda K (2011) Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis 218(2):470–478. https://doi.org/10.1016/j.atherosclerosis.2011.06.008
Kawai T, Takayanagi T, Forrester SJ, Preston KJ, Obama T, Tsuji T, Kobayashi T, Boyer MJ, Cooper HA, Kwok HF, Hashimoto T, Scalia R, Rizzo V, Eguchi S (2017) Vascular ADAM17 (a disintegrin and metalloproteinase domain 17) is required for angiotensin II/beta-aminopropionitrile-induced abdominal aortic aneurysm. Hypertension 70(5):959–963. https://doi.org/10.1161/HYPERTENSIONAHA.117.09822
Obama T, Tsuji T, Kobayashi T, Fukuda Y, Takayanagi T, Taro Y, Kawai T, Forrester SJ, Elliott KJ, Choi E, Daugherty A, Rizzo V, Eguchi S (2015) Epidermal growth factor receptor inhibitor protects against abdominal aortic aneurysm in a mouse model. Clin Sci (Lond) 128(9):559–565. https://doi.org/10.1042/cs20140696
Miyao M, Cicalese S, Cooper HA, Eguchi S (2019) Endoplasmic reticulum stress and mitochondrial biogenesis are potential therapeutic targets for abdominal aortic aneurysm. Clin Sci (Lond) 133(19):2023–2028. https://doi.org/10.1042/cs20190648
Cooper HA, Cicalese S, Preston KJ, Kawai T, Okuno K, Choi ET, Kasahara S, Uchida HA, Otaka N, Scalia R, Rizzo V, Eguchi S (2020) Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm. Cardiovasc Res. https://doi.org/10.1093/cvr/cvaa133
Forrester SJ, Preston KJ, Cooper HA, Boyer MJ, Escoto KM, Poltronetti AJ, Elliott KJ, Kuroda R, Miyao M, Sesaki H, Akiyama T, Kimura Y, Rizzo V, Scalia R, Eguchi S (2020) Mitochondrial fission mediates endothelial inflammation. Hypertension 76(1):267–276. https://doi.org/10.1161/hypertensionaha.120.14686
Miyao M, Cicalese S, Kawai T, Cooper HA, Boyer MJ, Elliott KJ, Forrester SJ, Kuroda R, Rizzo V, Hashimoto T, Scalia R, Eguchi S (2020) Involvement of senescence and mitochondrial fission in endothelial cell pro-inflammatory phenotype induced by angiotensin II. Int J Mol Sci. https://doi.org/10.3390/ijms21093112
Geng L, Wang W, Chen Y, Cao J, Lu L, Chen Q, He R, Shen W (2010) Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model. Exp Mol Pathol 89(1):72–81. https://doi.org/10.1016/j.yexmp.2010.05.006
Shen M, Hu M, Fedak PWM, Oudit GY, Kassiri Z (2018) Cell-specific functions of adam17 regulate the progression of thoracic aortic aneurysm. Circ Res 123(3):372–388. https://doi.org/10.1161/CIRCRESAHA.118.313181
Folkesson M, Li C, Frebelius S, Swedenborg J, Wagsater D, Williams KJ, Eriksson P, Roy J, Liu ML (2015) Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms. Thromb Haemost 114(6):1165–1174. https://doi.org/10.1160/TH14-10-0899
Satoh H, Nakamura M, Satoh M, Nakajima T, Izumoto H, Maesawa C, Kawazoe K, Masuda T, Hiramori K (2004) Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond) 106(3):301–306. https://doi.org/10.1042/CS20030189
Li Y, Yang C, Ma G, Cui L, Gu X, Chen Y, Zhao B, Wang H, Li K (2014) Analysis of ADAM17 polymorphisms and susceptibility to sporadic abdominal aortic aneurysm. Cell Physiol Biochem 33(5):1426–1438. https://doi.org/10.1159/000358708
Gerhardt T, Ley K (2015) Monocyte trafficking across the vessel wall. Cardiovasc Res 107(3):321–330. https://doi.org/10.1093/cvr/cvv147
Casagrande V, Menghini R, Menini S, Marino A, Marchetti V, Cavalera M, Fabrizi M, Hribal ML, Pugliese G, Gentileschi P, Schillaci O, Porzio O, Lauro D, Sbraccia P, Lauro R, Federici M (2012) Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 32(1):74–81. https://doi.org/10.1161/ATVBAHA.111.238402
Tang J, Frey JM, Wilson CL, Moncada-Pazos A, Levet C, Freeman M, Rosenfeld ME, Stanley ER, Raines EW, Bornfeldt KE (2018) Neutrophil and macrophage cell surface CSF-1 shed by ADAM17 drives mouse macrophage proliferation in acute and chronic inflammation. Mol Cell Biol. https://doi.org/10.1128/MCB.00103-18
Tsubota Y, Frey JM, Tai PW, Welikson RE, Raines EW (2013) Monocyte ADAM17 promotes diapedesis during transendothelial migration: identification of steps and substrates targeted by metalloproteinases. J Immunol 190(8):4236–4244. https://doi.org/10.4049/jimmunol.1300046
Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P (2001) TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol 166(3):1583–1589. https://doi.org/10.4049/jimmunol.166.3.1583
Willman CL, Stewart CC, Miller V, Yi TL, Tomasi TB (1989) Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1. J Exp Med 170(5):1559–1567. https://doi.org/10.1084/jem.170.5.1559
Metharom P, Martin K, Kumar AH, Sawhney N, Cronin MF, McCarthy DG, Maguire AR, Caplice NM (2011) Pleiotropic role for monocyte C-fms protein in response to vascular injury: potential therapeutic target. Atherosclerosis 216(1):74–82. https://doi.org/10.1016/j.atherosclerosis.2011.01.037
Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A (1993) The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171(3):223–229. https://doi.org/10.1002/path.1711710311
Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107(10):1255–1262. https://doi.org/10.1172/JCI11871
Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L (2001) Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med 194(2):205–218
Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K (2006) Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 203(5):1273–1282. https://doi.org/10.1084/jem.20052205
Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278(39):37459–37464. https://doi.org/10.1074/jbc.M305877200
Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S (1997) Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 46(12):2096–2101
Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D’Souza SE (2006) Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 281(6):3157–3164. https://doi.org/10.1074/jbc.M510797200
Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study. Circulation 96(12):4219–4225
Peschon J, Slack J, Reddy P, Stocking K, Sunnarborg S, Lee D, Russell W, Castner B, Johnson R, Fitzner J, Boyce R, Nelson N, Kozlosky C, Wolfson M, Rauch C, Cerretti D, Paxton R, March C, Black R (1998) An essential role for ectodomain shedding in mammalian development. Science 282(5392):1281–1284
Walcheck B (2003) ADAM-17-independent shedding of L-selectin. J Leukoc Biol 74(3):389–394. https://doi.org/10.1189/jlb.0403141
Walcheck B, Kahn J, Fisher JM, Wang BB, Fisk RS, Payan DG, Feehan C, Betageri R, Darlak K, Spatola AF, Kishimoto TK (1996) Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature 380(6576):720–723. https://doi.org/10.1038/380720a0
Schleiffenbaum B, Spertini O, Tedder TF (1992) Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 119(1):229–238
Nagano O, Murakami D, Hartmann D, De Strooper B, Saftig P, Iwatsubo T, Nakajima M, Shinohara M, Saya H (2004) Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165(6):893–902. https://doi.org/10.1083/jcb.200310024
Tole S, Durkan AM, Huang YW, Liu GY, Leung A, Jones LL, Taylor JA, Robinson LA (2010) Thromboxane prostanoid receptor stimulation induces shedding of the transmembrane chemokine CX3CL1 yet enhances CX3CL1-dependent leukocyte adhesion. Am J Physiol Cell Physiol 298(6):C1469-1480. https://doi.org/10.1152/ajpcell.00380.2009
Cooke VG, Naik MU, Naik UP (2006) Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion molecule-A-deficient mice. Arterioscler Thromb Vasc Biol 26(9):2005–2011. https://doi.org/10.1161/01.ATV.0000234923.79173.99
Naik MU, Naik UP (2006) Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha v beta 3 specific. J Cell Sci 119(Pt 3):490–499. https://doi.org/10.1242/jcs.02771
Woodfin A, Reichel CA, Khandoga A, Corada M, Voisin MB, Scheiermann C, Haskard DO, Dejana E, Krombach F, Nourshargh S (2007) JAM-A mediates neutrophil transmigration in a stimulus-specific manner in vivo: evidence for sequential roles for JAM-A and PECAM-1 in neutrophil transmigration. Blood 110(6):1848–1856. https://doi.org/10.1182/blood-2006-09-047431
Khandoga A, Kessler JS, Meissner H, Hanschen M, Corada M, Motoike T, Enders G, Dejana E, Krombach F (2005) Junctional adhesion molecule-A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial migration. Blood 106(2):725–733. https://doi.org/10.1182/blood-2004-11-4416
Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, Reiss K, Sarabi A, Lindbom L, Hackeng TM, Weber C, Ludwig A (2009) Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood 113(19):4799–4809. https://doi.org/10.1182/blood-2008-04-152330
Schaff U, Mattila PE, Simon SI, Walcheck B (2008) Neutrophil adhesion to E-selectin under shear promotes the redistribution and co-clustering of ADAM17 and its proteolytic substrate L-selectin. J Leukoc Biol 83(1):99–105. https://doi.org/10.1189/jlb.0507304
Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B (2009) Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol 182(4):2449–2457. https://doi.org/10.4049/jimmunol.0802770
Gooz P, Gooz M, Baldys A, Hoffman S (2009) ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem Biophys Res Commun 380(1):33–38. https://doi.org/10.1016/j.bbrc.2009.01.013
Kwak HI, Mendoza EA, Bayless KJ (2009) ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in three-dimensional collagen matrices. Matrix Biol 28(8):470–479. https://doi.org/10.1016/j.matbio.2009.07.007
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7(5):359–371. https://doi.org/10.1038/nrm1911
Kalinowski A, Plowes NJ, Huang Q, Berdejo-Izquierdo C, Russell RR, Russell KS (2010) Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J 24(7):2567–2575. https://doi.org/10.1096/fj.08-129072
Inoue Y, Shimazawa M, Nakamura S, Takata S, Hashimoto Y, Izawa H, Masuda T, Tsuruma K, Sakaue T, Nakayama H, Higashiyama S, Hara H (2018) Both autocrine signaling and paracrine signaling of HB-EGF enhance ocular neovascularization. Arterioscler Thromb Vasc Biol 38(1):174–185. https://doi.org/10.1161/ATVBAHA.117.310337
Kawasaki K, Freimuth J, Meyer DS, Lee MM, Tochimoto-Okamoto A, Benzinou M, Clermont FF, Wu G, Roy R, Letteboer TG, Ploos van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Westermann CJ, Coffey RJ Jr, Akhurst RJ (2014) Genetic variants of Adam17 differentially regulate TGFbeta signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci U S A 111(21):7723–7728. https://doi.org/10.1073/pnas.1318761111
Caolo V, Swennen G, Chalaris A, Wagenaar A, Verbruggen S, Rose-John S, Molin DG, Vooijs M, Post MJ (2015) ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. Angiogenesis 18(1):13–22. https://doi.org/10.1007/s10456-014-9443-4
Jin Y, Liu Y, Lin Q, Li J, Druso JE, Antonyak MA, Meininger CJ, Zhang SL, Dostal DE, Guan JL, Cerione RA, Peng X (2013) Deletion of Cdc42 enhances ADAM17-mediated vascular endothelial growth factor receptor 2 shedding and impairs vascular endothelial cell survival and vasculogenesis. Mol Cell Biol 33(21):4181–4197. https://doi.org/10.1128/MCB.00650-13
Raikwar NS, Liu KZ, Thomas CP (2014) N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domain. PLoS ONE 9(11):e112794. https://doi.org/10.1371/journal.pone.0112794
Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, Hinoki A, Eguchi S, Guaiquil V, Horiuchi K, Blobel CP (2010) Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 106(5):932–940. https://doi.org/10.1161/CIRCRESAHA.109.207415
Lucitti JL, Mackey JK, Morrison JC, Haigh JJ, Adams RH, Faber JE (2012) Formation of the collateral circulation is regulated by vascular endothelial growth factor-A and a disintegrin and metalloprotease family members 10 and 17. Circ Res 111(12):1539–1550. https://doi.org/10.1161/CIRCRESAHA.112.279109
Chikaraishi Y, Shimazawa M, Yokota K, Yoshino K, Hara H (2009) CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. Curr Neurovasc Res 6(3):140–147
Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y, Blobel C (2007) Cutting edge: TNF-α-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol 179(5):2686–2689
Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, Lee DC (2003) Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 22(11):2704–2716. https://doi.org/10.1093/emboj/cdg264
Canault M, Certel K, Schatzberg D, Wagner DD, Hynes RO (2010) The lack of ADAM17 activity during embryonic development causes hemorrhage and impairs vessel formation. PLoS ONE 5(10):e13433. https://doi.org/10.1371/journal.pone.0013433
Hassemer EL, Le Gall SM, Liegel R, McNally M, Chang B, Zeiss CJ, Dubielzig RD, Horiuchi K, Kimura T, Okada Y, Blobel CP, Sidjanin DJ (2010) The waved with open eyelids (woe) locus is a hypomorphic mouse mutation in Adam17. Genetics 185(1):245–255. https://doi.org/10.1534/genetics.109.113167
Wilson CL, Gough PJ, Chang CA, Chan CK, Frey JM, Liu Y, Braun KR, Chin MT, Wight TN, Raines EW (2013) Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults. Mech Dev 130(4–5):272–289. https://doi.org/10.1016/j.mod.2013.01.001
Zeng SY, Chen X, Chen SR, Li Q, Wang YH, Zou J, Cao WW, Luo JN, Gao H, Liu PQ (2013) Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression. Can J Cardiol 29(10):1310–1319. https://doi.org/10.1016/j.cjca.2013.04.026
Zeng SY, Lu HQ, Yan QJ, Zou J (2018) A reduction in ADAM17 expression is involved in the protective effect of the PPAR-alpha activator fenofibrate on pressure overload-induced cardiac hypertrophy. PPAR Res 2018:7916953. https://doi.org/10.1155/2018/7916953
Zeng SY, Yang L, Yan QJ, Gao L, Lu HQ, Yan PK (2019) Nox1/4 dual inhibitor GKT137831 attenuates hypertensive cardiac remodelling associating with the inhibition of ADAM17-dependent proinflammatory cytokines-induced signalling pathways in the rats with abdominal artery constriction. Biomed Pharmacother 109:1907–1914. https://doi.org/10.1016/j.biopha.2018.11.077
Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C (2009) Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 54(3):575–582. https://doi.org/10.1161/HYPERTENSIONAHA.108.127670
Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C (2011) MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 57(1):123–130. https://doi.org/10.1161/HYPERTENSIONAHA.110.159525
Fan D, Takawale A, Shen M, Wang W, Wang X, Basu R, Oudit GY, Kassiri Z (2015) Cardiomyocyte a disintegrin and metalloproteinase 17 (ADAM17) is essential in post-myocardial infarction repair by regulating angiogenesis. Circ Heart Fail 8(5):970–979. https://doi.org/10.1161/CIRCHEARTFAILURE.114.002029
Zheng DY, Zhao J, Yang JM, Wang M, Zhang XT (2016) Enhanced ADAM17 expression is associated with cardiac remodeling in rats with acute myocardial infarction. Life Sci. https://doi.org/10.1016/j.lfs.2016.02.097
Fan D, Takawale A, Shen M, Samokhvalov V, Basu R, Patel V, Wang X, Fernandez-Patron C, Seubert JM, Oudit GY, Kassiri Z (2016) A Disintegrin and metalloprotease-17 regulates pressure overload-induced myocardial hypertrophy and dysfunction through proteolytic processing of integrin beta1. Hypertension 68(4):937–948. https://doi.org/10.1161/HYPERTENSIONAHA.116.07566
Dou H, Feher A, Davila AC, Romero MJ, Patel VS, Kamath VM, Gooz MB, Rudic RD, Lucas R, Fulton DJ, Weintraub NL, Bagi Z (2017) Role of adipose tissue endothelial ADAM17 in age-related coronary microvascular dysfunction. Arterioscler Thromb Vasc Biol 37(6):1180–1193. https://doi.org/10.1161/ATVBAHA.117.309430
Satoh M, Ishikawa Y, Itoh T, Minami Y, Takahashi Y, Nakamura M (2008) The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur J Clin Invest 38(2):97–105. https://doi.org/10.1111/j.1365-2362.2007.01912.x
Shimoda Y, Satoh M, Nakamura M, Akatsu T, Hiramori K (2005) Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction. Clin Sci (Lond) 108(4):339–347. https://doi.org/10.1042/CS20040229
Rizza S, Copetti M, Cardellini M, Menghini R, Pecchioli C, Luzi A, Di Cola G, Porzio O, Ippoliti A, Romeo F, Pellegrini F, Federici M (2015) A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis. Atherosclerosis 239(2):459–464. https://doi.org/10.1016/j.atherosclerosis.2015.01.029
Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F (2005) Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11(8):867–874. https://doi.org/10.1038/nm1275
Kefaloyianni E, Muthu ML, Kaeppler J, Sun X, Sabbisetti V, Chalaris A, Rose-John S, Wong E, Sagi I, Waikar SS, Rennke H, Humphreys BD, Bonventre JV, Herrlich A (2016) ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight. https://doi.org/10.1172/jci.insight.87023
Li R, Wang T, Walia K, Gao B, Krepinsky JC (2018) Regulation of profibrotic responses by ADAM17 activation in high glucose requires its C-terminus and FAK. J Cell Sci. https://doi.org/10.1242/jcs.208629
Taniguchi K, Xia L, Goldberg HJ, Lee KW, Shah A, Stavar L, Masson EA, Momen A, Shikatani EA, John R, Husain M, Fantus IG (2013) Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 62(11):3874–3886. https://doi.org/10.2337/db12-1010
Qing X, Chinenov Y, Redecha P, Madaio M, Roelofs JJ, Farber G, Issuree PD, Donlin L, McLlwain DR, Mak TW, Blobel CP, Salmon JE (2018) iRhom2 promotes lupus nephritis through TNF-alpha and EGFR signaling. J Clin Invest 128(4):1397–1412. https://doi.org/10.1172/JCI97650
Beck Gooz M, Maldonado EN, Dang Y, Amria MY, Higashiyama S, Abboud HE, Lemasters JJ, Bell PD (2014) ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease. Am J Physiol Renal Physiol 307(5):F551-559. https://doi.org/10.1152/ajprenal.00218.2014
Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, van Goor H (2009) ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol 297(3):F781-790. https://doi.org/10.1152/ajprenal.90610.2008
Gutta S, Grobe N, Kumbaji M, Osman H, Saklayen M, Li G, Elased KM (2018) Increased urinary angiotensin converting enzyme 2 and neprilysin in patients with type 2 diabetes. Am J Physiol Renal Physiol 315(2):F263–F274. https://doi.org/10.1152/ajprenal.00565.2017
Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernandez E, Pascual J, Soler MJ (2018) Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfy240
Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernandez E, Pascual J, Soler MJ (2020) Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant 35(1):130–138. https://doi.org/10.1093/ndt/gfy240
Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Cunsolo V, Lauro D, Mauriello A, Smookler DS, Sbraccia P, Sesti G, Lee DC, Khokha R, Accili D, Lauro R (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115(12):3494–3505. https://doi.org/10.1172/JCI26052
Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M (2012) TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 61(2):454–462. https://doi.org/10.2337/db11-0613
Kaneko H, Anzai T, Horiuchi K, Morimoto K, Anzai A, Nagai T, Sugano Y, Maekawa Y, Itoh H, Yoshikawa T, Okada Y, Ogawa S, Fukuda K (2011) Tumor necrosis factor-α converting enzyme inactivation ameliorates high-fat diet-induced insulin resistance and altered energy homeostasis. Circ J 75(10):2482–2490. https://doi.org/10.1253/circj.CJ-11-0182
Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, Sbraccia P, Hribal ML, Lauro R, Federici M (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56(10):2541–2546. https://doi.org/10.2337/db07-0360
Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K (2002) Effect of TNF-alpha–converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39(2 Pt 2):578–580
de Meijer VE, Le HD, Meisel JA, Sharma AK, Popov Y, Puder M (2011) Tumor necrosis factor alpha-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS ONE 6(9):e25587. https://doi.org/10.1371/journal.pone.0025587
Badenes M, Amin A, Gonzalez-Garcia I, Felix I, Burbridge E, Cavadas M, Ortega FJ, de Carvalho E, Faisca P, Carobbio S, Seixas E, Pedroso D, Neves-Costa A, Moita LF, Fernandez-Real JM, Vidal-Puig A, Domingos A, Lopez M, Adrain C (2020) Deletion of iRhom2 protects against diet-induced obesity by increasing thermogenesis. Mol Metab 31:67–84. https://doi.org/10.1016/j.molmet.2019.10.006
Lian G, Li X, Zhang L, Zhang Y, Sun L, Zhang X, Liu H, Pang Y, Kong W, Zhang T, Wang X, Jiang C (2019) Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1alpha-ADAM17 pathway(). EBioMedicine 49:291–304. https://doi.org/10.1016/j.ebiom.2019.09.041
Badenes M, Amin A, González-García I, Félix I, Burbridge E, Cavadas M, Ortega FJ, de Carvalho É, Faísca P, Carobbio S, Seixas E, Pedroso D, Neves-Costa A, Moita LF, Fernández-Real JM, Vidal-Puig A, Domingos A, López M, Adrain C (2020) Deletion of iRhom2 protects against diet-induced obesity by increasing thermogenesis. Mol Metab 31:67–84. https://doi.org/10.1016/j.molmet.2019.10.006
Peng Q, Deng Y, Yang X, Leng X, Yang Y, Liu H (2016) Genetic variants of ADAM17 are implicated in the pathological process of Kawasaki disease and secondary coronary artery lesions via the TGF-beta/SMAD3 signaling pathway. Eur J Pediatr. https://doi.org/10.1007/s00431-016-2696-8
Junyent M, Parnell LD, Lai CQ, Arnett DK, Tsai MY, Kabagambe EK, Straka RJ, Province M, An P, Smith CE, Lee YC, Borecki I, Ordovas JM (2010) ADAM17_i33708A>G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the genetics of lipid lowering drugs and diet network study. Nutr Metab Cardiovasc Dis 20(10):698–705. https://doi.org/10.1016/j.numecd.2009.06.011
Morange PE, Tregouet DA, Godefroy T, Saut N, Bickel C, Rupprecht HJ, Lackner K, Barbaux S, Poirier O, Peiretti F, Nalbone G, Juhan-Vague I, Blankenberg S, Tiret L (2008) Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J Mol Med (Berl) 86(10):1153–1161. https://doi.org/10.1007/s00109-008-0375-6
Hartl D, May P, Gu W, Mayhaus M, Pichler S, Spaniol C, Glaab E, Bobbili DR, Antony P, Koegelsberger S, Kurz A, Grimmer T, Morgan K, Vardarajan BN, Reitz C, Hardy J, Bras J, Guerreiro R, Balling R, Schneider JG, Riemenschneider M, Aesg (2018) A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Mol Psychiatry. https://doi.org/10.1038/s41380-018-0091-8
Xie Y, Ma A, Wang B, Peng R, Jing Y, Wang D, Finnell RH, Qiao B, Wang Y, Wang H, Zheng Y (2019) Rare mutations of ADAM17 from TOFs induce hypertrophy in human embryonic stem cell-derived cardiomyocytes via HB-EGF signaling. Clin Sci (Lond) 133(2):225–238. https://doi.org/10.1042/cs20180842
Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf F, Toynbee M, Walne A, O’Toole EA, Martin JE, Lindley K, Vulliamy T, Abrams DJ, MacDonald TT, Harper JI, Kelsell DP (2011) Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med 365(16):1502–1508. https://doi.org/10.1056/NEJMoa1100721
Bandsma RH, van Goor H, Yourshaw M, Horlings RK, Jonkman MF, Schölvinck EH, Karrenbeld A, Scheenstra R, Kömhoff M, Rump P, Koopman-Keemink Y, Nelson SF, Escher JC, Cutz E, Martín MG (2015) Loss of ADAM17 is associated with severe multiorgan dysfunction. Hum Pathol 46(6):923–928. https://doi.org/10.1016/j.humpath.2015.02.010
Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102(4):1186–1195. https://doi.org/10.1182/blood-2002-12-3775
Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S, Ludwig A (2004) The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172(10):6362–6372
Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen KJ, Rose-John S (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 278(40):38829–38839. https://doi.org/10.1074/jbc.M210584200
Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22(10):3716–3727. https://doi.org/10.1096/fj.08-109033
Hikita A, Tanaka N, Yamane S, Ikeda Y, Furukawa H, Tohma S, Suzuki R, Tanaka S, Mitomi H, Fukui N (2009) Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-alpha. Biochem Cell Biol 87(4):581–593. https://doi.org/10.1139/o09-015
Zhang C, Tian L, Chi C, Wu X, Yang X, Han M, Xu T, Zhuang Y, Deng K (2010) Adam10 is essential for early embryonic cardiovascular development. Dev Dyn 239(10):2594–2602. https://doi.org/10.1002/dvdy.22391
Mehta V, Fields L, Evans IM, Yamaji M, Pellet-Many C, Jones T, Mahmoud M, Zachary I (2018) VEGF (vascular endothelial growth factor) induces NRP1 (neuropilin-1) cleavage via ADAMs (a disintegrin and metalloproteinase) 9 and 10 to generate novel carboxy-terminal NRP1 fragments that regulate angiogenic signaling. Arterioscler Thromb Vasc Biol. https://doi.org/10.1161/ATVBAHA.118.311118
Donners MM, Wolfs IM, Olieslagers S, Mohammadi-Motahhari Z, Tchaikovski V, Heeneman S, van Buul JD, Caolo V, Molin DG, Post MJ, Waltenberger J (2010) A disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis. Arterioscler Thromb Vasc Biol 30(11):2188–2195. https://doi.org/10.1161/ATVBAHA.110.213124
Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P, Reiss K (2008) ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res 102(10):1192–1201. https://doi.org/10.1161/CIRCRESAHA.107.169805
Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164(5):769–779. https://doi.org/10.1083/jcb.200307137
Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, Raines EW, Dunbar AJ, Dempsey PJ (2005) ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 280(3):1826–1837. https://doi.org/10.1074/jbc.M408804200
Yan Y, Shirakabe K, Werb Z (2002) The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 158(2):221–226. https://doi.org/10.1083/jcb.200112026
Shitomi Y, Thogersen IB, Ito N, Leitinger B, Enghild JJ, Itoh Y (2015) ADAM10 controls collagen signaling and cell migration on collagen by shedding the ectodomain of discoidin domain receptor 1 (DDR1). Mol Biol Cell 26(4):659–673. https://doi.org/10.1091/mbc.E14-10-1463
Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 281(48):36846–36855. https://doi.org/10.1074/jbc.M606656200
Jiang J, Wu S, Wang W, Chen S, Peng J, Zhang X, Wu Q (2011) Ectodomain shedding and autocleavage of the cardiac membrane protease corin. J Biol Chem 286(12):10066–10072. https://doi.org/10.1074/jbc.M110.185082
Herzog C, Haun RS, Ludwig A, Shah SV, Kaushal GP (2014) ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A. J Biol Chem 289(19):13308–13322. https://doi.org/10.1074/jbc.M114.559088
Bozkulak EC, Weinmaster G (2009) Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 29(21):5679–5695. https://doi.org/10.1128/MCB.00406-09
Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, Le Naour F, Gutwein P, Ludwig A, Rubinstein E, Altevogt P (2006) A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 393(Pt 3):609–618. https://doi.org/10.1042/BJ20051013
Yokozeki T, Wakatsuki S, Hatsuzawa K, Black RA, Wada I, Sehara-Fujisawa A (2007) Meltrin beta (ADAM19) mediates ectodomain shedding of Neuregulin beta1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. Genes Cells 12(3):329–343. https://doi.org/10.1111/j.1365-2443.2007.01060.x
Sun C, Wu MH, Guo M, Day ML, Lee ES, Yuan SY (2010) ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc Res 87(2):348–355. https://doi.org/10.1093/cvr/cvq060
Sun C, Wu MH, Lee ES, Yuan SY (2012) A disintegrin and metalloproteinase 15 contributes to atherosclerosis by mediating endothelial barrier dysfunction via Src family kinase activity. Arterioscler Thromb Vasc Biol 32(10):2444–2451. https://doi.org/10.1161/ATVBAHA.112.252205
Miyamae Y, Mochizuki S, Shimoda M, Ohara K, Abe H, Yamashita S, Kazuno S, Ohtsuka T, Ochiai H, Kitagawa Y, Okada Y (2016) ADAM28 is expressed by epithelial cells in human normal tissues And protects from C1q-induced cell death. FEBS J. https://doi.org/10.1111/febs.13693
Shimoda M, Hashimoto G, Mochizuki S, Ikeda E, Nagai N, Ishida S, Okada Y (2007) Binding of ADAM28 to P-selectin glycoprotein ligand-1 enhances P-selectin-mediated leukocyte adhesion to endothelial cells. J Biol Chem 282(35):25864–25874. https://doi.org/10.1074/jbc.M702414200
McGinn OJ, English WR, Roberts S, Ager A, Newham P, Murphy G (2011) Modulation of integrin alpha4beta1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration. Cell Biol Int 35(10):1043–1053. https://doi.org/10.1042/CBI20100885
Kelly K, Hutchinson G, Nebenius-Oosthuizen D, Smith AJ, Bartsch JW, Horiuchi K, Rittger A, Manova K, Docherty AJ, Blobel CP (2005) Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice. Dev Dyn 232(1):221–231. https://doi.org/10.1002/dvdy.20221
Weskamp G, Cai H, Brodie TA, Higashyama S, Manova K, Ludwig T, Blobel CP (2002) Mice Lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol Cell Biol 22(5):1537–1544. https://doi.org/10.1128/mcb.22.5.1537-1544.2002
Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, Ludwig T, Chiusaroli R, Baron R, Preissner KT, Manova K, Blobel CP (2003) Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol 23(16):5614–5624
Chen C, Huang X, Sheppard D (2006) ADAM33 is not essential for growth and development and does not modulate allergic asthma in mice. Mol Cell Biol 26(18):6950–6956. https://doi.org/10.1128/MCB.00646-06
Guaiquil VH, Swendeman S, Zhou W, Guaiquil P, Weskamp G, Bartsch JW, Blobel CP (2010) ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl) 88(5):497–505. https://doi.org/10.1007/s00109-010-0591-8
Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP (2009) ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 29(10):2694–2703. https://doi.org/10.1128/MCB.01460-08
Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, Saftig P (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11(21):2615–2624
Zhou HM, Weskamp G, Chesneau V, Sahin U, Vortkamp A, Horiuchi K, Chiusaroli R, Hahn R, Wilkes D, Fisher P, Baron R, Manova K, Basson CT, Hempstead B, Blobel CP (2004) Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol 24(1):96–104
Kurohara K, Komatsu K, Kurisaki T, Masuda A, Irie N, Asano M, Sudo K, Nabeshima Y, Iwakura Y, Sehara-Fujisawa A (2004) Essential roles of meltrin beta (ADAM19) in heart development. Dev Biol 267(1):14–28. https://doi.org/10.1016/j.ydbio.2003.10.021
Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kassiri Z, Lopaschuk GD, Fernandez-Patron C (2009) Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 119(18):2480–2489. https://doi.org/10.1161/CIRCULATIONAHA.108.835488
Glomski K, Monette S, Manova K, De Strooper B, Saftig P, Blobel CP (2011) Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood 118(4):1163–1174. https://doi.org/10.1182/blood-2011-04-348557
Farber G, Hurtado R, Loh S, Monette S, Mtui J, Kopan R, Quaggin S, Meyer-Schwesinger C, Herzlinger D, Scott RP, Blobel CP (2018) Glomerular endothelial cell maturation depends on ADAM10, a key regulator of Notch signaling. Angiogenesis 21(2):335–347. https://doi.org/10.1007/s10456-018-9599-4
Alabi R, Glomski K, Haxaire C, Weskamp G, Monette S, Blobel CP (2016) ADAM10-Dependent signaling through notch1 and notch4 controls development of organ-specific vascular beds. Circ Res. https://doi.org/10.1161/CIRCRESAHA.115.307738
Guo Q, Wang Y, Tripathi P, Manda KR, Mukherjee M, Chaklader M, Austin PF, Surendran K, Chen F (2015) Adam10 mediates the choice between principal cells and intercalated cells in the kidney. J Am Soc Nephrol 26(1):149–159. https://doi.org/10.1681/ASN.2013070764
van der Vorst EP, Jeurissen M, Wolfs IM, Keijbeck A, Theodorou K, Wijnands E, Schurgers L, Weber S, Gijbels MJ, Hamers AA, Dreymueller D, Rose-John S, de Winther MP, Ludwig A, Saftig P, Biessen EA, Donners MM (2015) Myeloid A disintegrin and metalloproteinase domain 10 deficiency modulates atherosclerotic plaque composition by shifting the balance from inflammation toward fibrosis. Am J Pathol 185(4):1145–1155. https://doi.org/10.1016/j.ajpath.2014.11.028
Jana S, Chute M, Hu M, Winkelaar G, Owen CA, Oudit GY, Kassiri Z (2020) ADAM (a disintegrin and metalloproteinase) 15 deficiency exacerbates Ang II (Angiotensin II)-induced aortic remodeling leading to abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 40(8):1918–1934. https://doi.org/10.1161/atvbaha.120.314600
Musumeci G, Coleman R, Imbesi R, Magro G, Parenti R, Szychlinska MA, Scuderi R, Cina CS, Castorina S, Castrogiovanni P (2014) ADAM-10 could mediate cleavage of N-cadherin promoting apoptosis in human atherosclerotic lesions leading to vulnerable plaque: a morphological and immunohistochemical study. Acta Histochem 116(7):1148–1158. https://doi.org/10.1016/j.acthis.2014.06.002
Yang K, Lu L, Liu Y, Zhang Q, Pu LJ, Wang LJ, Zhu ZB, Wang YN, Meng H, Zhang XJ, Du R, Chen QJ, Shen WF (2013) Increase of ADAM10 level in coronary artery in-stent restenosis segments in diabetic minipigs: high ADAM10 expression promoting growth and migration in human vascular smooth muscle cells via Notch 1 and 3. PLoS ONE 8(12):e83853. https://doi.org/10.1371/journal.pone.0083853
Al-Fakhri N, Wilhelm J, Hahn M, Heidt M, Hehrlein FW, Endisch AM, Hupp T, Cherian SM, Bobryshev YV, Lord RS, Katz N (2003) Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 89(4):808–823. https://doi.org/10.1002/jcb.10550
Levula M, Paavonen T, Valo T, Pelto-Huikko M, Laaksonen R, Kahonen M, Huovila A, Lehtimaki T, Tarkka M, Mennander AA (2011) A disintegrin and metalloprotease -8 and -15 and susceptibility for ascending aortic dissection. Scand J Clin Lab Invest 71(6):515–522. https://doi.org/10.3109/00365513.2011.591939
Theodorou K, van der Vorst EPC, Gijbels MJ, Wolfs IMJ, Jeurissen M, Theelen TL, Sluimer JC, Wijnands E, Cleutjens JP, Li Y, Jansen Y, Weber C, Ludwig A, Bentzon JF, Bartsch JW, Biessen EAL, Donners M (2017) Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression. Sci Rep 7(1):11670. https://doi.org/10.1038/s41598-017-10549-x
Pelisek J, Pongratz J, Deutsch L, Reeps C, Stadlbauer T, Eckstein HH (2012) Expression and cellular localization of metalloproteases ADAMs in high graded carotid artery lesions. Scand J Clin Lab Invest 72(8):648–656. https://doi.org/10.3109/00365513.2012.734394
Holloway JW, Laxton RC, Rose-Zerilli MJ, Holloway JA, Andrews AL, Riaz Z, Wilson SJ, Simpson IA, Ye S (2010) ADAM33 expression in atherosclerotic lesions and relationship of ADAM33 gene variation with atherosclerosis. Atherosclerosis 211(1):224–230. https://doi.org/10.1016/j.atherosclerosis.2010.02.023
Figarska SM, Vonk JM, van Diemen CC, Postma DS, Boezen HM (2013) ADAM33 gene polymorphisms and mortality. A Prospect Cohort Study PLoS One 8(7):e67768. https://doi.org/10.1371/journal.pone.0067768
Raitoharju E, Seppala I, Levula M, Kuukasjarvi P, Laurikka J, Nikus K, Huovila AP, Oksala N, Klopp N, Illig T, Laaksonen R, Karhunen PJ, Viik J, Lehtinen R, Pelto-Huikko M, Tarkka M, Kahonen M, Lehtimaki T (2011) Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts. Atherosclerosis 218(1):127–133. https://doi.org/10.1016/j.atherosclerosis.2011.05.005
Vuohelainen V, Raitoharju E, Levula M, Lehtimaki T, Pelto-Huikko M, Honkanen T, Huovila A, Paavonen T, Tarkka M, Mennander A (2011) Myocardial infarction induces early increased remote ADAM8 expression of rat hearts after cardiac arrest. Scand J Clin Lab Invest 71(7):553–562. https://doi.org/10.3109/00365513.2011.591424
Melenhorst WB, van den Heuvel MC, Timmer A, Huitema S, Bulthuis M, Timens W, van Goor H (2006) ADAM19 expression in human nephrogenesis and renal disease: associations with clinical and structural deterioration. Kidney Int 70(7):1269–1278. https://doi.org/10.1038/sj.ki.5001753
Melenhorst WB, van den Heuvel MC, Stegeman CA, van der Leij J, Huitema S, van den Berg A, van Goor H (2006) Upregulation of ADAM19 in chronic allograft nephropathy. Am J Transplant 6(7):1673–1681. https://doi.org/10.1111/j.1600-6143.2006.01384.x
Lee AC, Lam JK, Shiu SW, Wong Y, Betteridge DJ, Tan KC (2015) Serum level of soluble receptor for advanced glycation end products is associated with a disintegrin and metalloproteinase 10 in type 1 diabetes. PLoS ONE 10(9):e0137330. https://doi.org/10.1371/journal.pone.0137330
Jowett JB, Okada Y, Leedman PJ, Curran JE, Johnson MP, Moses EK, Goring HH, Mochizuki S, Blangero J, Stone L, Allen H, Mitchell C, Matthews VB (2012) ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-alpha. Immunol Cell Biol 90(10):966–973. https://doi.org/10.1038/icb.2012.44
Bahia MS, Silakari O (2010) Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders. Chem Biol Drug Des 75(5):415–443. https://doi.org/10.1111/j.1747-0285.2010.00950.x
DasGupta S, Murumkar PR, Giridhar R, Yadav MR (2009) Current perspective of TACE inhibitors: a review. Bioorg Med Chem 17(2):444–459. https://doi.org/10.1016/j.bmc.2008.11.067
Moss ML, Sklair-Tavron L, Nudelman R (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4(6):300–309. https://doi.org/10.1038/ncprheum0797
Mulder GM, Melenhorst WB, Celie JW, Kloosterhuis NJ, Hillebrands JL, Ploeg RJ, Seelen MA, Visser L, van Dijk MC, van Goor H (2012) ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis. Nephrol Dial Transplant 27(5):2114–2122. https://doi.org/10.1093/ndt/gfr583
Souza DG, Ferreira FL, Fagundes CT, Amaral FA, Vieira AT, Lisboa RA, Andrade MV, Trifilieff A, Teixeira MM (2007) Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice. Eur J Pharmacol 571(1):72–80. https://doi.org/10.1016/j.ejphar.2007.05.058
Dell KM, Nemo R, Sweeney WE Jr, Levin JI, Frost P, Avner ED (2001) A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int 60(4):1240–1248. https://doi.org/10.1046/j.1523-1755.2001.00963.x
Sweeney WE Jr, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED (2003) Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 64(4):1310–1319. https://doi.org/10.1046/j.1523-1755.2003.00232.x
Long C, Wang Y, Herrera AH, Horiuchi K, Walcheck B (2010) In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli-mediated peritonitis. J Leukoc Biol 87(6):1097–1101. https://doi.org/10.1189/jlb.1109763
Wong E, Cohen T, Romi E, Levin M, Peleg Y, Arad U, Yaron A, Milla ME, Sagi I (2016) Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo. Sci Rep 6:35598. https://doi.org/10.1038/srep35598
Thabet MM, Huizinga TW (2006) Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 7(11):1014–1019
Issuree PD, Maretzky T, McIlwain DR, Monette S, Qing X, Lang PA, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD, Yarilina A, Horiuchi K, Ivashkiv LB, Mak TW, Salmon JE, Blobel CP (2013) iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest 123(2):928–932. https://doi.org/10.1172/JCI66168
Aktas B, Pozgajova M, Bergmeier W, Sunnarborg S, Offermanns S, Lee D, Wagner DD, Nieswandt B (2005) Aspirin induces platelet receptor shedding via ADAM17 (TACE). J Biol Chem 280(48):39716–39722. https://doi.org/10.1074/jbc.M507762200
Gomez-Gaviro MV, Gonzalez-Alvaro I, Dominguez-Jimenez C, Peschon J, Black RA, Sanchez-Madrid F, Diaz-Gonzalez F (2002) Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem 277(41):38212–38221. https://doi.org/10.1074/jbc.M205142200
Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16(4):1115–1125. https://doi.org/10.1681/ASN.2004070573
Arcidiacono MV, Yang J, Fernandez E, Dusso A (2015) The induction of C/EBPbeta contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease. Nephrol Dial Transplant 30(3):423–433. https://doi.org/10.1093/ndt/gfu311
Dusso A, Arcidiacono MV, Yang J, Tokumoto M (2010) Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 121(1–2):193–198. https://doi.org/10.1016/j.jsbmb.2010.03.064
Yang WS, Kim HW, Lee JM, Han NJ, Lee MJ, Park SK (2015) 1,25-dihydroxyvitamin D3 causes ADAM10-dependent ectodomain shedding of tumor necrosis factor receptor 1 in vascular smooth muscle cells. Mol Pharmacol 87(3):533–542. https://doi.org/10.1124/mol.114.097147
Garton K, Gough P, Blobel C, Murphy G, Greaves D, Dempsey P, Raines E (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001
Schulte A, Schulz B, Andrzejewski MG, Hundhausen C, Mletzko S, Achilles J, Reiss K, Paliga K, Weber C, John SR, Ludwig A (2007) Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. Biochem Biophys Res Commun 358(1):233–240. https://doi.org/10.1016/j.bbrc.2007.04.100
Horiuchi K, Morioka H, Takaishi H, Akiyama H, Blobel CP, Toyama Y (2009) Ectodomain shedding of FLT3 ligand is mediated by TNF-alpha converting enzyme. J Immunol 182(12):7408–7414. https://doi.org/10.4049/jimmunol.0801931
Kawaguchi N, Horiuchi K, Becherer JD, Toyama Y, Besmer P, Blobel CP (2007) Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. J Cell Sci 120(Pt 6):943–952. https://doi.org/10.1242/jcs.03403
Li N, Wang Y, Forbes K, Vignali KM, Heale BS, Saftig P, Hartmann D, Black RA, Rossi JJ, Blobel CP, Dempsey PJ, Workman CJ, Vignali DA (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26(2):494–504. https://doi.org/10.1038/sj.emboj.7601520
Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A (2008) Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68(15):6368–6376. https://doi.org/10.1158/0008-5472.CAN-07-6768
Boutet P, Aguera-Gonzalez S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT, Vales-Gomez M (2009) Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182(1):49–53
Lum L, Wong B, Josien R, Becherer J, Erdjument-Bromage H, Schlöndorff J, Tempst P, Choi Y, Blobel C (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274(19):13613–13618
Kenny PA, Bissell MJ (2007) Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117(2):337–345. https://doi.org/10.1172/JCI29518
Althoff K, Mullberg J, Aasland D, Voltz N, Kallen K, Grotzinger J, Rose-John S (2001) Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins. Biochem J 353(Pt 3):663–672
Young J, Yu X, Wolslegel K, Nguyen A, Kung C, Chiang E, Kolumam G, Wei N, Wong WL, DeForge L, Townsend MJ, Grogan JL (2010) Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 51(1):78–86. https://doi.org/10.1016/j.cyto.2010.03.003
Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y (2008) Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A 105(22):7809–7814
Lambert DW, Clarke NE, Hooper NM, Turner AJ (2008) Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett 582(2):385–390. https://doi.org/10.1016/j.febslet.2007.11.085
Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280(34):30113–30119. https://doi.org/10.1074/jbc.M505111200
Liu Q, Zhang J, Tran H, Verbeek MM, Reiss K, Estus S, Bu G (2009) LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener 4:17. https://doi.org/10.1186/1750-1326-4-17
Hansen H, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann E, Lange H, Lemke H, Engert A (2004) The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 18(7):893–895
Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J (2003) Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 278(35):32801–32809. https://doi.org/10.1074/jbc.M209993200
Peng M, Guo S, Yin N, Xue J, Shen L, Zhao Q, Zhang W (2010) Ectodomain shedding of Fcalpha receptor is mediated by ADAM10 and ADAM17. Immunology 130(1):83–91. https://doi.org/10.1111/j.1365-2567.2009.03215.x
Määttä J, Sundvall M, Junttila T, Peri L, Laine V, Isola J, Egeblad M, Elenius K (2006) Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 17(1):67–79. https://doi.org/10.1091/mbc.E05-
Rio C, Buxbaum J, Peschon J, Corfas G (2000) Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275(14):10379–10387
Schantl J, Roza M, Van Kerkhof P, Strous G (2004) The growth hormone receptor interacts with its sheddase, the tumour necrosis factor-alpha-converting enzyme (TACE). Biochem J 377(Pt 2):379–384
Zhang Q, Thomas S, Xi S, Smithgall T, Siegfried J, Kamens J, Gooding W, Grandis J (2004) SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64(17):6166–6173
Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH, Wagner DD (2004) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 95(7):677–683. https://doi.org/10.1161/01.RES.0000143899.73453.11
Rabie T, Strehl A, Ludwig A, Nieswandt B (2005) Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 280(15):14462–14468. https://doi.org/10.1074/jbc.M500041200
Bender M, Hofmann S, Stegner D, Chalaris A, Bosl M, Braun A, Scheller J, Rose-John S, Nieswandt B (2010) Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 116(17):3347–3355. https://doi.org/10.1182/blood-2010-06-289108
Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, Jones SA, Rose-John S, Scheller J (2007) Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110(6):1748–1755. https://doi.org/10.1182/blood-2007-01-067918
Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J (2000) Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 267(9):2624–2631
Sommer C, Lee S, Gulseth HL, Jensen J, Drevon CA, Birkeland KI (2018) Soluble leptin receptor predicts insulin sensitivity and correlates with upregulation of metabolic pathways in men. J Clin Endocrinol Metab 103(3):1024–1032. https://doi.org/10.1210/jc.2017-02126
Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, Bu PL, Yang JM, Liu XL, Zhang MX, Gao F, Zhang C, Zhang Y (2011) CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J Lipid Res 52(5):923–933. https://doi.org/10.1194/jlr.M015156
Leksa V, Loewe R, Binder B, Schiller HB, Eckerstorfer P, Forster F, Soler-Cardona A, Ondrovicova G, Kutejova E, Steinhuber E, Breuss J, Drach J, Petzelbauer P, Binder BR, Stockinger H (2011) Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation. Circ Res 108(6):676–685. https://doi.org/10.1161/CIRCRESAHA.110.234732
Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A (2007) Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 282(1):436–444. https://doi.org/10.1074/jbc.M605451200
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A (2000) A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5(2):207–216
Cho RW, Park JM, Wolff SB, Xu D, Hopf C, Kim JA, Reddy RC, Petralia RS, Perin MS, Linden DJ, Worley PF (2008) mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. Neuron 57(6):858–871. https://doi.org/10.1016/j.neuron.2008.01.010
Weskamp G, Schlondorff J, Lum L, Becherer JD, Kim TW, Saftig P, Hartmann D, Murphy G, Blobel CP (2004) Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem 279(6):4241–4249. https://doi.org/10.1074/jbc.M307974200
Chow JP, Fujikawa A, Shimizu H, Suzuki R, Noda M (2008) Metalloproteinase- and gamma-secretase-mediated cleavage of protein-tyrosine phosphatase receptor type Z. J Biol Chem 283(45):30879–30889. https://doi.org/10.1074/jbc.M802976200
Pruessmeyer J, Martin C, Hess FM, Schwarz N, Schmidt S, Kogel T, Hoettecke N, Schmidt B, Sechi A, Uhlig S, Ludwig A (2010) A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J Biol Chem 285(1):555–564. https://doi.org/10.1074/jbc.M109.059394
Yang WS, Kim JJ, Lee MJ, Lee EK, Park SK (2018) ADAM17-Mediated ectodomain shedding of toll-like receptor 4 as a negative feedback regulation in lipopolysaccharide-activated aortic endothelial cells. Cell Physiol Biochem 45(5):1851–1862. https://doi.org/10.1159/000487876
Diaz-Rodriguez E, Montero JC, Esparis-Ogando A, Yuste L, Pandiella A (2002) Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell 13(6):2031–2044. https://doi.org/10.1091/mbc.01-11-0561
Hermey G, Sjogaard SS, Petersen CM, Nykjaer A, Gliemann J (2006) Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J 395(2):285–293. https://doi.org/10.1042/BJ20051364
Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, Baselga J, Arribas J, Canals F (2006) Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol Cell Biol 26(13):5086–5095. https://doi.org/10.1128/MCB.02380-05
Li Y, Brazzell J, Herrera A, Walcheck B (2006) ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding. Blood 108(7):2275–2279. https://doi.org/10.1182/blood-2006-02-005827
Franzke CW, Tasanen K, Borradori L, Huotari V, Bruckner-Tuderman L (2004) Shedding of collagen XVII/BP180: structural motifs influence cleavage from cell surface. J Biol Chem 279(23):24521–24529. https://doi.org/10.1074/jbc.M308835200
Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11(2):162–171. https://doi.org/10.1038/ncb1824
Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P, Reiss K (2005) L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol 25(20):9040–9053. https://doi.org/10.1128/MCB.25.20.9040-9053.2005
Ruhe JE, Streit S, Hart S, Ullrich A (2006) EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cell Signal 18(9):1515–1527. https://doi.org/10.1016/j.cellsig.2005.12.003
Kalus I, Bormann U, Mzoughi M, Schachner M, Kleene R (2006) Proteolytic cleavage of the neural cell adhesion molecule by ADAM17/TACE is involved in neurite outgrowth. J Neurochem 98(1):78–88. https://doi.org/10.1111/j.1471-4159.2006.03847.x
Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280(20):19543–19550. https://doi.org/10.1074/jbc.M410943200
Singh RJ, Mason JC, Lidington EA, Edwards DR, Nuttall RK, Khokha R, Knauper V, Murphy G, Gavrilovic J (2005) Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res 67(1):39–49. https://doi.org/10.1016/j.cardiores.2005.02.020
Murthy A, Defamie V, Smookler DS, Di Grappa MA, Horiuchi K, Federici M, Sibilia M, Blobel CP, Khokha R (2010) Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest 120(8):2731–2744. https://doi.org/10.1172/JCI42686
Gschwind A, Hart S, Fischer O, Ullrich A (2003) TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22(10):2411–2421
Sahin U, Blobel CP (2007) Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 581(1):41–44. https://doi.org/10.1016/j.febslet.2006.11.074
Schafer B, Gschwind A, Ullrich A (2004) Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23(4):991–999. https://doi.org/10.1038/sj.onc.1207278
Wang Y, Sul HS (2006) Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol 26(14):5421–5435. https://doi.org/10.1128/MCB.02437-05
Zhu L, Bergmeier W, Wu J, Jiang H, Stalker T, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H, Tamagnone L, Wagner D, Milla M, Brass L (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A 104(5):1621–1626
Motani K, Kosako H (2018) Activation of stimulator of interferon genes (STING) induces ADAM17-mediated shedding of the immune semaphorin SEMA4D. J Biol Chem 293(20):7717–7726. https://doi.org/10.1074/jbc.RA118.002175
Ali N, Knauper V (2007) Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. J Biol Chem 282(52):37378–37388. https://doi.org/10.1074/jbc.M702170200
Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273(43):27765–27767
Slack B, Ma L, Seah C (2001) Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme. Biochem J 357(Pt 3):787–794
Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK (2010) Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 88(6):1201–1205. https://doi.org/10.1189/jlb.0410235
Gandhi R, Yi J, Ha J, Shi H, Ismail O, Nathoo S, Bonventre JV, Zhang X, Gunaratnam L (2014) Accelerated receptor shedding inhibits kidney injury molecule-1 (KIM-1)-mediated efferocytosis. Am J Physiol Renal Physiol 307(2):F205-221. https://doi.org/10.1152/ajprenal.00638.2013
Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR (2007) Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A 104(50):19796–19801. https://doi.org/10.1073/pnas.0709805104
Zhang Y, Wang Y, Zhou D, Zhang LS, Deng FX, Shu S, Wang LJ, Wu Y, Guo N, Zhou J, Yuan ZY (2019) Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT1R/ROS/p38 MAPK/ADAM17 pathway. Am J Physiol Cell Physiol 317(4):C776–C787. https://doi.org/10.1152/ajpcell.00145.2019
Kummer MP, Maruyama H, Huelsmann C, Baches S, Weggen S, Koo EH (2009) Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase. J Biol Chem 284(4):2296–2306. https://doi.org/10.1074/jbc.M808904200
Alfa Cisse M, Sunyach C, Slack BE, Fisher A, Vincent B, Checler F (2007) M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity. J Neurosci 27(15):4083–4092. https://doi.org/10.1523/JNEUROSCI.5293-06.2007
Moller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, Scheller J (2013) A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem 288(48):34529–34544. https://doi.org/10.1074/jbc.M113.488478
Malapeira J, Esselens C, Bech-Serra JJ, Canals F, Arribas J (2011) ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of vasorin. Oncogene 30(16):1912–1922. https://doi.org/10.1038/onc.2010.565
Naus S, Reipschlager S, Wildeboer D, Lichtenthaler SF, Mitterreiter S, Guan Z, Moss ML, Bartsch JW (2006) Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem 387(3):337–346. https://doi.org/10.1515/BC.2006.045
Fourie AM, Coles F, Moreno V, Karlsson L (2003) Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 278(33):30469–30477. https://doi.org/10.1074/jbc.M213157200
Gomez-Gaviro M, Dominguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E, Fourie A, Tugores A, Valenzuela-Fernandez A, Mollinedo F, Sanchez-Madrid F, Diaz-Gonzalez F (2007) Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-Selectin shedding. J Immunol 178(12):8053–8063. https://doi.org/10.4049/jimmunol.178.12.8053
Bartsch JW, Wildeboer D, Koller G, Naus S, Rittger A, Moss ML, Minai Y, Jockusch H (2010) Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection. J Neurosci 30(36):12210–12218. https://doi.org/10.1523/JNEUROSCI.1520-10.2010
Matsuno O, Miyazaki E, Nureki S, Ueno T, Kumamoto T, Higuchi Y (2006) Role of ADAM8 in experimental asthma. Immunol Lett 102(1):67–73. https://doi.org/10.1016/j.imlet.2005.07.006
Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E (1998) A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17(24):7260–7272. https://doi.org/10.1093/emboj/17.24.7260
Parkin E, Harris B (2009) A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J Neurochem 108(6):1464–1479. https://doi.org/10.1111/j.1471-4159.2009.05907.x
Tousseyn T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, Maes E, Snellinx A, Serneels L, Nyabi O, Annaert W, Saftig P, Hartmann D, De Strooper B (2009) ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem 284(17):11738–11747. https://doi.org/10.1074/jbc.M805894200
Grabowska MM, Sandhu B, Day ML (2012) EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal 24(2):532–538. https://doi.org/10.1016/j.cellsig.2011.10.004
van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R, Vooijs M (2009) Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 284(45):31018–31027. https://doi.org/10.1074/jbc.M109.006775
Hofmann S, Vogtle T, Bender M, Rose-John S, Nieswandt B (2012) The SLAM family member CD84 is regulated by ADAM10 and calpain in platelets. J Thromb Haemost 10(12):2581–2592. https://doi.org/10.1111/jth.12013
Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L, Hampel H, Novak B, Kremmer E, Tahirovic S, Edbauer D, Lichtenthaler SF, Schmid B, Willem M, Haass C (2013) Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci 33(18):7856–7869. https://doi.org/10.1523/JNEUROSCI.3372-12.2013
Aghababaei M, Hogg K, Perdu S, Robinson WP, Beristain AG (2015) ADAM12-directed ectodomain shedding of E-cadherin potentiates trophoblast fusion. Cell Death Differ 22(12):1970–1984. https://doi.org/10.1038/cdd.2015.44
Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM (2000) ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278(3):511–515. https://doi.org/10.1006/bbrc.2000.3835
Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, Toyama Y, Hartmann D, Saftig P, Blobel CP (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18(1):176–188. https://doi.org/10.1091/mbc.E06-01-0014
Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8(1):35–40. https://doi.org/10.1038/nm0102-35
Najy AJ, Day KC, Day ML (2008) The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 283(26):18393–18401. https://doi.org/10.1074/jbc.M801329200
Xie B, Shen J, Dong A, Swaim M, Hackett SF, Wyder L, Worpenberg S, Barbieri S, Campochiaro PA (2008) An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. FASEB J 22(8):2775–2783. https://doi.org/10.1096/fj.07-099283
Wei P, Zhao YG, Zhuang L, Ruben S, Sang QX (2001) Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. Biochem Biophys Res Commun 280(3):744–755. https://doi.org/10.1006/bbrc.2000.4200
Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP (2003) Catalytic properties of ADAM19. J Biol Chem 278(25):22331–22340. https://doi.org/10.1074/jbc.M302781200
Shirakabe K, Wakatsuki S, Kurisaki T, Fujisawa-Sehara A (2001) Roles of meltrin beta /ADAM19 in the processing of neuregulin. J Biol Chem 276(12):9352–9358. https://doi.org/10.1074/jbc.M007913200
Yoshikawa A, Aizaki Y, Kusano K, Kishi F, Susumu T, Iida S, Ishiura S, Nishimura S, Shichiri M, Senbonmatsu T (2011) The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space. Hypertens Res 34(5):599–605. https://doi.org/10.1038/hr.2010.284
Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y (2004) ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 315(1):79–84. https://doi.org/10.1016/j.bbrc.2004.01.022
Mochizuki S, Tanaka R, Shimoda M, Onuma J, Fujii Y, Jinno H, Okada Y (2010) Connective tissue growth factor is a substrate of ADAM28. Biochem Biophys Res Commun 402(4):651–657. https://doi.org/10.1016/j.bbrc.2010.10.077
Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, Okano H, Okada Y (2012) Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst 104(12):906–922. https://doi.org/10.1093/jnci/djs232
Zou J, Zhu F, Liu J, Wang W, Zhang R, Garlisi CG, Liu YH, Wang S, Shah H, Wan Y, Umland SP (2004) Catalytic activity of human ADAM33. J Biol Chem 279(11):9818–9830. https://doi.org/10.1074/jbc.M309696200
Funding
This work was supported by National Institute of Health grants, HL128324 (S.E.), HL133248 (S.E.), DK111042 (R.S. and S.E.), and NS109382 (S.E.).
Author information
Authors and Affiliations
Contributions
TK and SE proposed the idea and writing. KE and RS proof-read the article and performed critical revision in organization and discussion.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kawai, T., Elliott, K.J., Scalia, R. et al. Contribution of ADAM17 and related ADAMs in cardiovascular diseases. Cell. Mol. Life Sci. 78, 4161–4187 (2021). https://doi.org/10.1007/s00018-021-03779-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-021-03779-w